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ABSTRACT
Background    The purpose of this study was to investi-
gate factors related to feelings of being burdened in type 
1 diabetes patients using continuous subcutaneous insu-
lin infusion (CSII) therapy.
Methods    Participants were 106 subscribers to the Dia-
betes Network’s e-mail newsletter. An online survey was 
used. Eligible participants were aged at least 20 years, 
had type 1 diabetes, and were using CSII. Survey ques-
tions concerned whether participants found CSII burden-
some, and seven potential reasons for feelings of burden. 
Analysis calculated correlations among participants’ 
demographic and treatment-related factors, and among 
participants’ reasons for feeling CSII to be burdensome.
Results    Regarding demographic and treatment-related 
factors, gender was found to be weakly negatively cor-
related with the following variables: employment status, 
and whether participants had discussed their concerns 
with a doctor. Employment status was found to be weak-
ly correlated with diabetes duration; employment status 
and diabetes duration were found to be weakly correlat-
ed with age. Regarding reasons for finding CSII therapy 
burdensome, “It takes too much time” was found to be 
strongly positively correlated with “It interferes with 
work responsibilities”; 16 weak positive correlations 
were also found.
Conclusion    To explain our results, we suggest that 
medical expenses, glycemic control, scheduling outpa-
tient visits around home and work responsibilities, and 
interacting with medical staff may have caused partici-
pants to find CSII therapy burdensome. Most partici-
pants had never discussed their treatment concerns with 
a doctor. This suggests that nurses may be able to miti-
gate feeling burdened in participants using CSII therapy.
Key words    continuous subcutaneous insulin infusion; 
feeling burdened; related factors; type 1 diabetes
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Type 1 diabetes may be treated using either multiple dai-
ly injection (MDI) therapy, or continuous subcutaneous 
insulin infusion (CSII) therapy, which uses an insulin 
pump. Recent advances in insulin pump technology are 
associated with an increasing number of patients with 
type 1 diabetes adopting CSII. Meta-analyses compar-
ing CSII with MDI have reported that CSII is associated 
with reduced blood glucose level fluctuation, improved 
HbA1c levels, and less frequent hypoglycemia and hy-
perglycemia.1–5 Partly in consequence, numerous stud-
ies have reported that CSII is associated with improved 
quality of life and that CSII patient satisfaction levels are 
high. A Japanese study of satisfaction in type 1 diabetes 
patients using CSII obtained similar results;6 however, 
Shetty (2010)7 and Saarinen (2014)8 have reported that 
although patients tend to feel that CSII facilitates daily 
control of blood glucose, patients may also feel inconve-
nienced, as the pump’s needle must be kept in place, the 
pump is heavy and conspicuous if worn outside clothing, 
and the equipment can be cumbersome to operate. 
 Previous studies in other countries have examined 
CSII’s effectiveness, operability, and effect on patients’ 
daily lives; however, Japanese research addressing CSII 
has been limited to case studies. There is no apparent 
extant Japanese research examining the psychological 
aspects of CSII’s use—in particular, how patients may 
feel burdened by using CSII. We therefore examined pa-
tients’ feelings of being burdened and potentially related 
underlying factors, to suggest means of improving nurs-
ing care for type 1 diabetes patients using CSII.
SUBJECTS AND METHODS 
Participants and Data collection
This study was performed with the cooperation of Eli 
Lilly Japan (Kobe, Japan). Participants were 106 sub-
scribers to the Diabetes Network’s e-mail newsletter.9 
Participants were aged at least 20 years, and were us-
ing CSII to manage their type 1 diabetes. Participants 
completed the survey online. Questions concerned seven 
demographic and treatment-related factors (gender, age, 
marital status, employment status, duration of diabetes, 
monthly medical expense, and whether the participant 
had ever discussed treatment concerns with a doctor), 
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whether participants found CSII burdensome, and seven 
possible reasons for feeling burdened (“It’s expensive,” 
“Glycemic control is poor,” “I dislike the treatment,” “It 
takes too much time,” “It interferes with my work re-
sponsibilities,” “Wait times for checkups are long,” and “I 
have problems interacting with the medical staff.”) The 
survey period was March—April 2013.
Data analysis
SPSS ver. 22 (IBM, Armonk, NY) was used for statisti-
cal analysis. Pearson correlation coefficients were calcu-
lated to examine correlations among demographic and 
treatment-related factors, and among reasons for feeling 
burdened by CSII.
Ethical considerations
Eli Lilly Japan reviewed this study regarding ethical 
considerations. Prospective participants were informed 
online that survey results would not be used for any pur-
pose other than those of the study, that participation was 
anonymous and voluntary, that no data or results would 
be attributed to any individual, and that refusing to par-
ticipate entailed no penalty. Participants who indicated 
consent, answered survey questions, and submitted the 
survey were considered to have provided Eli Lilly Japan 
with their informed consent.
RESULTS
Participant demographics and treatment-related 
factors (Table 1)
Table 1 shows results for participants’ demographic and 
treatment-related factors.
CSII’s perceived burden on participants, and par-
ticipants’ reasons (Table 2)
Table 2 shows the number of participants who felt bur-
dened by CSII (Yes/No), and participants’ reasons for 
any feelings of being burdened. Sixty-three participants 
(59.4%) replied “Yes”; 43 (40.6%) replied “No.” Among 
reasons for replies, the most frequent response was “It’s 
expensive,” given by 49 respondents (46.2%).
Correlations among demographic and treatment-
related factors (Table 3)
Table 3 shows correlations among participants’ demo-
graphic and treatment-related factors. Gender was found 
to be weakly negatively correlated with employment sta-
tus, and whether the patient had ever discussed treatment 
concerns with a doctor. Employment status and diabetes 
duration were found to be weakly correlated with age; 
employment status was found to be weakly positively 
correlated with diabetes duration.
Table 1. Participant demographics and treatment-
related factors
Item n (%)
Gender
Male  23 (21.7)
Female  83 (78.3)
Age
(years)
< 30  14 (13.2)
30–39  39 (36.8)
40–49  27 (25.5)
50–59  19 (17.9)
60–69  5 (6.6)
Employment status
employed  51 (48.1)
unemployed  55 (51.9)
Marital status
Duration of diabetes
(years)
single  62 (58.5)
married  44 (41.5)
< 5  26 (24.5)
5–10  13 (12.3)
11–20  29 (27.4)
> 20  38 (35.8)
Monthly  medical expenses
(yen)
< 5000  4 (3.8)
5000–10000  1 (0.9)
10000–15000  10 (9.4)
15000–20000  48 (45.3)
> 20000  43 (40.6)
Whether the participant had ever
discussed treatment concerns with
a doctor
Yes  33 (31.7)
No  71 (68.3)
Table 2. CSII’s perceived burden on participants, and 
participants’ reasons
CSII’s perceived burden on participants n (%)
Yes 63 (59.4)
No 43 (40.6)
participants’ reasons n (%)
It’s expensive 49 (46.2)
Glycemic control is poor 30 (28.3)
I dislike the treatment 21 (19.8)
It takes too much time 23 (21.7)
It interferes with my work responsibilities 22 (20.8)
Wait times for checkups are long 16 (15.1)
I have problems interacting with the medical staff 11 (10.4)
CSII, continuous subcutaneous insulin infusion.
Correlations among reasons for feeling burdened 
by CSII (Table 4)
Table 4 shows correlation coefficients for reasons for 
feeling burdened by CSII. The following weak positive 
correlations were found:
i) “It’s expensive” correlated with “Glycemic control is 
poor,” “I dislike the treatment,” “It takes too much 
time,” “It interferes with my work responsibilities,” 
and “Wait times for checkups are long.” 
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ii) “Glycemic control is poor” correlated with “It takes 
too much time,” “It interferes with my work respon-
sibilities,” “I dislike the treatment,” and “I have prob-
lems interacting with the medical staff.”
iii) “I dislike the treatment” correlated with “It takes too 
much time,” “It interferes with my work responsibili-
ties,” and “Wait times for checkups are long,” and “I 
have problems interacting with the medical staff.”
iv) “It takes too much time” correlated with “Wait times 
for checkups are long” and “I have problems interact-
ing with the medical staff.”
v) “Wait times for checkups are long” correlated with “I 
have problems interacting with the medical staff.”
 Further, a strong positive correlation was found be-
tween “It takes too much time” and “It interferes with 
my work responsibilities.”
DISCUSSION
Correlations between demographic and treat-
ment-related factors in type 1 diabetes patients 
using CSII
Several explanations may be suggested for gender’s 
observed weak negative correlations with other factors. 
Type 1 diabetes characteristically develops in youth, and 
is more frequent in girls (Ministry of Health, Labor and 
Welfare Patient Survey, 2011).10 Approximately 80% 
of this study’s participants were women, and the large 
majority was middle-aged, with women aged 30–39 
and 40–49 accounting for around 37% and 26% of the 
sample, respectively. Correlations observed with gender 
in this study may reflect greater difficulty balancing 
work and childcare among women, as childcare im-
poses additional responsibilities on female patients. The 
number of diabetic patients able to balance work and 
Table 3. Correlations among demographic and treatment-related factors
Gender Age Maritalstatus
Employment 
status
Duration of 
diabetes
Monthly med-
ical expense
Whether the 
participant had 
ever discussed 
treatment 
concerns with 
a doctor
Gender –0.378** –0.211* –0.272** –0.075 –0.022 –0.234*
Age –0.378** 0.153 0.193* 0.254** 0.010 0.188
Marital status –0.211* 0.153 0.083 –0.020 0.060 –0.015
Employment status –0.272** 0.193* 0.83 0.351** –0.126 0.130
Duration of diabetes –0.075 0.254** –0.020 0.351** 0.094 0.155
Monthly medical expense –0.022 0.010 0.060 –0.126 0.094 0.185
Whether the participant 
had ever discussed treat-
ment concerns with a doc-
tor
–0.234* 0.188 –0.015 0.130 0.155 0.185
*P < 0.05. **P < 0.01. CSII, continuous subcutaneous insulin infusion.
Table 4. Correlations among reasons for feeling burdened by CSII
It’s expensive Glycemic control is poor
I dislike the 
treatment
It takes too 
much time
It interferes 
with my work 
responsibili-
ties
Wait times for 
checkups are 
long
I have prob-
lems interact-
ing with the 
medical staff
It’s expensive 0.384** 0.346** 0.384** 0.365** 0.349** 0.179
Glycemic control is poor 0.384** 0.476** 0.330** 0.350** 0.145 0.266**
I dislike the treatment 0.346** 0.476** 0.370** 0.329** 0.319** 0.218*
It takes too much time 0.384** 0.330** 0.370** 0.972** 0.226* 0.195*
It interferes with my work 
responsibilities 0.365** 0.350** 0.329** 0.972** 0.174 0.130
Wait times for checkups 
are long 0.349** 0.145 0.319** 0.226* 0.174 0.394**
I have problems interacting 
with the medical staff 0.179 0.266** 0.218* 0.195* 0.130 0.394**
*P < 0.05. **P < 0.01. CSII, continuous subcutaneous insulin infusion.
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childcare may be small. Further, female gender’s nega-
tive correlation with patients’ having discussed treatment 
concerns with a doctor may reflect the preponderance 
of female participants: rather than talking with doctors, 
female participants may prefer to discuss management 
of health, childcare, housework, and work with nurses, 
due to feelings of greater familiarity or of better overall 
understanding of participants’ lives. 
 Age was found to be weakly positively correlated 
with diabetes duration and employment status. This may 
be because many participants had had diabetes for a long 
time, with 27% and 36% reporting diabetes durations of 
10–19 and 20 years or more, respectively. These partici-
pants therefore likely developed type 1 diabetes in their 
youth. Research has shown that patients who have had 
diabetes for a long time gradually acquire individualized 
means of self-managing their condition. These patients 
are therefore able to adjust their lives to accommodate 
changes in treatment regimen, using self-management 
methods gathered from experience.11-12 It may therefore 
be conjectured that older patients switching from MDI 
to CSII were able to mitigate interruptions to their work 
by implementing acquired self-management strategies—
thus explaining the weak positive correlation between 
age and employment status.
 In Japan, CSII is frequently introduced to type 1 
diabetes patients when glycemic control is difficult using 
MDI; this may partly explain the weak correlation found 
between employment status and diabetes duration. It is 
possible that the majority of this study’s participants had 
switched from MDI to CSII. Compared to MDI, CSII 
more effectively lowers blood glucose and HbA1c levels, 
reducing the frequency of hypoglycemia and hypergly-
cemia, and stabilizing glycemic control, better enabling 
patients to attain physical and mental stability.8 Patients 
who have had diabetes for longer may have switched to 
CSII earlier, to better maintain glycemic control in order 
to continue working. Further, a longer duration of diabe-
tes raises the likelihood that patients have self-disclosed 
to their workmates that they are diabetic; disclosure con-
tributes to the quality of patients’ social relationships, 
and increases patients’ social support.13
Correlations among reasons for feeling CSII to be 
burdensome 
Almost 60% of participants indicated that they felt bur-
dened by CSII. Some participants may have indicated 
that they felt burdened because, even with CSII, they 
faced the constant burden of type 1 diabetes in their 
daily life. Many participants were mature women aged 
30–40 years, who performed various social roles such 
as wife, daughter-in-law, or mother. It is also possible 
that, as acquiring techniques for using the insulin pump 
and establishing basal rates takes time, it may likewise 
take time for patients to meet the conditions necessary 
to improving glycemic control.7 Some participants may 
have been in this position; this could account for some 
participant indications of how burdensome CSII is.
 Regarding relationships among reasons for feeling 
burdened by CSII therapy, “It’s expensive” was found to 
be weakly positively correlated with “Glycemic control 
is poor” and “I dislike the treatment.” Accumulating 
medical expenses, which include checkup and medica-
tion costs as well as medical test fees and transportation 
costs, may contribute to feelings of being burdened by 
CSII. Large medical expenses can lead to reduction of 
other household expenditure, and to attempts to reduce 
treatment costs by such means as independently decid-
ing to reduce frequency or quantity of self-administered 
insulin, which may worsen glycemic control, as well as 
the patient’s diabetes.14, 15 These effects tend to reduce 
patients’ treatment motivation; this may partly explain 
the observed positive correlations between the above 
reasons and feelings of how burdensome CSII is. Ad-
ditionally, type 1 diabetes patients, including those using 
CSII, incur monthly checkup fees. To get a checkup, 
patients must visit a doctor during work breaks, or take 
time off work. Paid leave can be difficult to ask for, 
and at busy times, it may even be difficult to attend a 
checkup during work breaks. This may explain why “It’s 
expensive” was found to be positively correlated with 
“It interferes with work responsibilities” and with “Wait 
times for a checkup are long.”
 The reason “Glycemic control is poor” was found to 
be weakly positively correlated with “I dislike the treat-
ment,” “It interferes with work responsibilities,” “It takes 
too much time,” and “I have problems interacting with 
the medical staff.” Patients may unrealistically expect 
that blood glucose control will immediately improve 
after switching to CSII; if it does not, they may consider 
that CSII does not work for them, and discontinue CSII 
in favor of MDI.8, 16 In this study, patients who had dis-
continued CSII were officially ineligible for participa-
tion; however, as the survey was online, it is possible 
that such patients responded. Further, any breakdowns 
in glycemic control may cause patients to blame CSII, 
feel that CSII is ineffective, or believe that CSII may 
not work for them. Further, if glycemic control is lost 
for a long time, patients may be more likely to begin to 
dislike everything related to CSII, and feel CSII to be 
burdensome in general. These considerations may partly 
explain the observed positive correlations with “Glycemic 
control is poor.”
 The reason “I dislike the treatment” was found to 
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be weakly positively correlated with “It takes too much 
time,” “It interferes with my work responsibilities,” “Wait 
times for checkups are long,” and “I have problems 
interacting with the medical staff.” This may be partly 
explained as follows: once a patient begins to think neg-
atively about treatment (similarly to regarding glycemic 
control, above), he or she may begin to dislike anything 
connected to CSII, greatly increasing the likelihood that 
he or she will feel burdened. 
 Finally, the reason “It takes too much time” was 
found to be strongly positively correlated with “It inter-
feres with my work responsibilities,” and weakly cor-
related with “It takes too much time” and “Wait times 
for checkups are too long.” In Japan, long wait times 
are not limited to diabetes outpatient clinics. In general, 
wait times for medical examinations are longer than the 
examination times themselves (Ministry of Health, La-
bor and Welfare Survey on Visits to Physicians, 2011).17 
Regarding the strong correlation with “It interferes with 
my work responsibilities,” when wait time is included, 
patients spend a large amount of time getting checkups; 
this may affect patients’ work. Regarding the weak posi-
tive correlation with “Wait times for checkups are long” 
and “I have problems interacting with the medical staff,” 
longer wait times may induce fatigue, and in combina-
tion with wait times that exceed examination times, this 
may cause patients to become irritated with medical 
staff.
Suggestions for nursing
Patients with type 1 diabetes who use CSII must contin-
ue treatment for their entire lives; this may feel burden-
some. In this study, however, many participants, includ-
ing participants who felt burdened by their treatment, 
had never discussed their concerns with a doctor. These 
participants may have referred to nurses for advice when 
troubled or worried, as mitigating patients’ feelings of 
being burdened because of treatment is a key nursing 
role. To support patients’ continuation of CSII therapy, 
medical staff must help patients manage CSII’s effects 
on patients’ home and work lives, as well as directly sup-
porting CSII’s use. For example, younger patients, who 
may have less available time, often only attend outpatient 
treatment when they are compelled to. In such cases, the 
nurse, with whom a patient may feel most familiar, must 
proactively undertake communication with patients in 
order to address any feelings of being burdened because 
of treatment, and engage team healthcare resources in 
order to allow personnel to respond who are able to meet 
the patients’ needs. If nurses are unable to respond in a 
suitable way to the patient’s issues, any existing feelings 
of being burdened by treatment may go unresolved. It is 
therefore important for nurses to routinely develop their 
ability to discover and understand factors that may be 
troubling patients or causing them to feel burdened by 
their treatment.
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